Marker Therapeutics Highlights MAR-T Cell Innovations
Marker Therapeutics, Inc. (NASDAQ: MRKR), a clinical-stage immuno-oncology firm, is making waves in the field of T cell therapy. The company's Chief Executive Officer, Dr. Juan Vera, will be prominently featured in a virtual event titled "Seven Years After FDA Approval – Have CD19 CAR-T Cells Met Expectations?" This event, conducted by Demy-Colton in collaboration with the WBB Research Institute, takes place on May 28, 2025, at 11:00 a.m. EDT.
Insights into CAR-T Cell Therapies
The upcoming one-hour event is set to shed light on the advancements in CAR-T cell therapies. Industry experts will gather to discuss the evolution, challenges, and future potential of these therapies. Dr. Vera will present Marker’s innovative MAR-T cell therapy platform, designed to enhance effectiveness while addressing previous limitations associated with traditional CAR-T therapies.
Panel of Experts
Joining Dr. Vera are several esteemed panelists, recognized for their significant contributions to immuno-oncology:
- Dr. Helen Heslop: Professor at Baylor College of Medicine, actively involved in cell and gene therapy.
- Dr. Malcolm Brenner: Founding Director at Baylor College of Medicine and a key figure in cell and gene therapy research.
- Dr. Manali Kamdar: Associate Professor at the University of Colorado, renowned for her work in oncology.
- Dr. Geoffrey Shouse: Assistant Professor at City of Hope, contributing significantly to cancer research.
- Dr. Juan Vera: President and CEO of Marker Therapeutics.
Virtual Webcast Agenda
The agenda for the May 28 virtual webcast is structured as follows, fostering a comprehensive dialogue on CAR-T cell therapies:
- 11:00 – 11:05 am: Opening remarks by Sara Demy, CEO of Demy-Colton, and Steve Brozak, President and Co-founder of WBB Securities.
- 11:05 – 11:10 am: Dr. Helen Heslop discusses the shortcomings of CAR-T therapy.
- 11:10 – 11:15 am: Dr. Malcolm Brenner gives insights on overcoming current limitations.
- 11:15 – 11:20 am: Dr. Vera presents MAR-T cells as a new solution to unmet needs.
- 11:20 – 11:50 am: An engaging roundtable discussion moderated by Dr. Richard Marfuggi, Medical Director of WBB Research Institute, featuring extensive dialogue among the expert panelists.
- 11:50 – 12:00 pm: Q&A session, inviting audience interaction.
This roundtable is expected to be accessible globally, encouraging widespread participation and fostering critical discussions necessary for advancing treatment in the oncology field.
About Marker Therapeutics, Inc.
Founded at Baylor College of Medicine, Marker Therapeutics is based in Houston, Texas, and specializes in developing next-generation T cell therapies aimed at treating both hematological malignancies and solid tumors. The company has seen positive responses in clinical trials with over 200 patients, showcasing the potential of its autologous and allogeneic MAR-T cell therapies.
With a mission to enhance patient outcomes, Marker Therapeutics prioritizes operational excellence while securing funding from state and federal grant programs dedicated to cancer research. Their efforts in the field continue to gain momentum, promising innovations that could change the landscape of cancer treatment.
Frequently Asked Questions
What is the purpose of the upcoming webcast?
The webcast aims to address the current state and future possibilities of CAR-T cell therapies, featuring insights from leading experts.
Who will be participating in the expert panel?
Key opinion leaders in the field, such as Dr. Helen Heslop, Dr. Malcolm Brenner, Dr. Manali Kamdar, and Dr. Geoffrey Shouse will join Dr. Juan Vera in the discussion.
How does the MAR-T cell therapy differ from traditional CAR-T therapies?
MAR-T cell therapy employs a unique multi-antigen approach that aims to mitigate challenges faced by conventional CAR-T therapies.
How can participants join the discussion during the webcast?
Participants are encouraged to register in advance to actively engage in the roundtable discussions during the event.
What are the expected outcomes of the discussion?
The discussion aims to yield vital insights into current challenges in cancer treatment and potential advancements that can benefit patient care.
